| Name | Title | Contact Details |
|---|
NextGate`s mission is to address the fundamental challenge of data management in the healthcare industry: the uncertainties and missed opportunities caused by duplicate and disconnected records in a data population. While implementing interface engine technology for hospitals in the early 1990s, we noticed a troubling trend – as application systems became integrated and exchanged data with each other, problems caused by duplicate and incomplete patient records (previously confined to one system and its MPI) multiplied and contaminated the data quality of other systems. Because this technical issue could impact a patient`s health, we made it our goal to find a solution. The result was MatchMetrix®, a technology platform that invokes probabilistic and other algorithms to identify duplicate and potentially duplicate records within a single data set or across multiple data sets. All records are assigned a unique ID that serves as an enterprise-wide universal key for accurate identification and efficient data exchange. Duplicate records are merged, related records are linked together, and all of them are indexed into a trusted, consistent, and reliable registry accessible to any authorized application or user. We continue to develop solutions that help manage information that facilitates care team collaboration with accuracy and reliability.
Velcera is a Yardley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
Massachusetts Hospital Association is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Burlington, MA. To find more information about Massachusetts Hospital Association, please visit www.mhalink.org
Inflexxion Inc is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Newton Upper Falls, MA. To find more information about Inflexxion Inc, please visit www.inflexxion.com